scholarly journals Distinguishing Radiation Pneumonitis from Local Tumour Recurrence Following SBRT for Lung Cancer

2020 ◽  
Vol Volume 13 ◽  
pp. 1-23
Author(s):  
Bernd Frerker ◽  
Guido Hildebrandt
Keyword(s):  
Lung Cancer ◽  
Radiation Pneumonitis ◽  
Tumour Recurrence ◽  
Local Tumour Recurrence ◽  
Local Tumour

Percutaneous radiofrequency versus microwave ablation for the treatment of colorectal liver metastases.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 401-401
Author(s):  
Lawrence Bonne ◽  
Katja De Paepe ◽  
Nicos Fotiadis ◽  
Naureen Starling ◽  
Ian Chau ◽  
...  
Keyword(s):  
Overall Survival ◽  
Liver Metastasis ◽  
Liver Metastases ◽  
Demographic Data ◽  
Primary Tumour ◽  
Tumour Recurrence ◽  
Tumour Control ◽  
Local Tumour Recurrence ◽  
History Of ◽  
Local Tumour

401 Background: Microwave (MWA) and radiofrequency (RFA) ablation are commonly used for the treatment of unresectable liver metastases from colorectal cancer (CRC). MWA has a few theoretical advantages over RFA (active heating, less affected by heat sink effect, larger ablation zones, faster) however limited data exists on this field. Our aim was to analyse the safety and efficacy of MWA and RFA in the treatment of CRC liver metastases. Methods: All patients with unresectable CRC liver metastasis who were treated with RFA or MWA in a single center between March 2006 and December 2016 were included. Medical records and imaging studies were reviewed retrospectively for demographic data, to assess for local tumour recurrence and overall survival and to evaluate ablation-related adverse events. Results: 456 ablations were performed in 193 patients (123 men) with a median age of 66 (range 32-91). The majority of patients had a history of surgery of the primary tumour (n=170, 88,1%) and systemic chemotherapy (n=183, 94,8%). 68 patients had a history of liver surgery (35,2%). RFA was used in 343 procedures (75,2%) and MWA in 113 (24,8%). Median number of procedures per patient was 2 (range 1-10). Median lesion size was 17mm (range 3-80mm). Mean follow-up per lesion was 2.0 years in the RFA group and 1.3 years in the MWA group. Local tumour recurrence rate was 45% for RFA and 28% for MWA, with a hazard ratio of 0.6 in favour of MWA (95% CI 0.4-0.9). Two and five year overall survival rates from diagnosis of liver metastasis were 88% and 35% for RFA and 89% and 66% for MWA, respectively. Complications were reported in 43 of 456 procedures (9,4%); In 8,2% of RFAs (n=28) and 13,3% of MWAs (n=15). Complications classified as CTCAE grade 3 or higher were: haemothorax requiring surgery (n=1 for RFA), biloma (n=2 for RFA & MWA), biliary stricture (n=2 for RFA and n=1 MWA), liver failure (n=2 for RFA), liver abscess (n=1 RFA), pneumonia (n=2 for RFA) and pulmonary embolism (n=1 RFA). Segmental portal vein occlusion was only seen with MWA (n=2; 1,8%). One patient died due to multi-organ failure post RFA. Conclusions: MWA could achieve better local tumour control compared with RFA in the treatment of CRC liver metastasis, with slightly higher complication rate.

scholarly journals Inhibition of Post-Surgery Tumour Recurrence via a Sprayable Chemoimmunotherapy Gel Releasing PD-L1 Antibody and Platelet-Derived Exosomes

2021 ◽  
Author(s):  
Jian Zhao ◽  
Hao Ye ◽  
Qi Lu ◽  
Kaiyuan Wang ◽  
Xiaofeng Chen ◽  
...  
Keyword(s):  
Cytotoxic T Cells ◽  
Tumour Cells ◽  
Tumour Recurrence ◽  
Fibrin Gel ◽  
Tumour Metastasis ◽  
Post Surgery ◽  
Local Tumour Recurrence ◽  
Local Tumour

Abstract Background: Melanoma is the most serious type of skin cancer, and surgery is an effective method to treat melanoma. Unfortunately, local residual micro-infiltrated tumour cells and systemic circulating tumour cells (CTCs) are significant causes of treatment failure, leading to tumour recurrence and metastasis. Methods: Exosomes were isolated from platelets by differential centrifugation, and exosome-loaded doxorubicin (PexD) was prepared by mixing exosomes with doxorubicin (DOX). PexD and an anti-PD-L1 monoclonal antibody (aPD-L1) were coencapsulated in fibrin gel. The synergistic antitumour efficacy of the gel containing PexD and aPD-L1 was assessed both in vitro and in vivo. Results: Herein, we developed an in situ-formed bioresponsive gel combined with chemoimmunotherapeutic agents as a drug reservoir that could effectively inhibit both local tumour recurrence and tumour metastasis. In comparison with a DOX solution, PexD could better bind to tumour cells, induce more tumour immunogenic cell death (ICD) and promote a stronger antitumour immune response. PexD could enter the blood circulation through damaged blood vessels to track and eliminate CTCs. The concurrent release of aPD-L1 at the tumour site could impair the PD-1/PD-L1 pathway and restore the tumour-killing effect of cytotoxic T cells. This chemoimmunotherapeutic strategy triggered relatively strong T cell immune responses, significantly improving the tumour immune microenvironment. Conclusion: Our findings indicated that the immunotherapeutic fibrin gel could “awaken” the host innate immune system to inhibit both local tumour recurrence postsurgery and metastatic potential, thus, it could serve as a promising approach to prevent tumour recurrence.

Understanding and preventing local tumour recurrence

2009 ◽  
Vol 10 (7) ◽  
pp. 645-646 ◽  
Author(s):  
Michael Höckel ◽  
Nadja Dornhöfer
Keyword(s):  
Tumour Recurrence ◽  
Local Tumour Recurrence ◽  
Local Tumour
Sign in / Sign up

Export Citation Format

Share Document